Global Insulin Glargine

Insulin Glargine Comprehensive Study by Application (Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)), Forms (Liquid, Tablet, Syrup, Cream, Gel), Side Effect (Rash, Hives, Itching, Wheezing), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Sales, Other Distribution Channel) Players and Region - Global Market Outlook to 2030

Insulin Glargine Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Insulin Glargine is a long-acting insulin that maintains sugar management throughout the day. It functions similarly to the body's natural insulin. Insulin promotes sugar reuptake in muscle and fat cells while also suppressing sugar synthesis in the liver. Insulin Glargine is a synthetic insulin that closely resembles human insulin. It has a long-lasting and consistent (constant) influence on blood sugar levels that lasts the entire day. As a result, it can be used once a day. It is used to treat adults with type 2 diabetes and adults and children with type 1 diabetes. According to AMA Research, the market for Insulin Glargine is expected to register a CAGR of 6.1% during the forecast period to 2030. This growth is primarily driven by Rising Prevalence Of Diabetes Disease.

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Pharmaceuticals sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Cipla Inc. (India), Sanofi-Aventis (France), Novo Nordisk (Denmark), WOCKHARDT (India), Dongbro Pharmaceutical, (China), Sekisui Diagnostics, LLC, (United States), Biocon Biologics, (India), Trumac Healthcare Ltd (India), ADOCIA (France) and Biogenomics Limited. (India), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In December 2021, Eris Lifesciences entered the insulin market through a joint venture with MJ Biopharm. This venture, named Eris MJ Biopharm Ltd., will engage in marketing and distribution of Human and Analogue Insulin including Aspart, Glargine, and Lispro, and GLP-1 agonists.
In November 2021, Viatris and Biocon Biologics announced the U.S. launch of interchangeable biosimilars SEMGLEE® (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to control high blood sugar in diabetes patients.The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Influencing Trend:
Increasing Use Of Insulin Glargine For Diabetes Disease

Market Growth Drivers:
Rising Prevalence Of Diabetes Disease

Challenges:
Stringent Government Regulatory Requirement For The Approval Of Insulin Glargine

Restraints:
Side Effect Associated By Use Of Insulin Glargine

Opportunities:
Rising Healthcare Expenditure and Growth In Research And Development And Subsequent Technological Advancements

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Insulin Glargine Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Insulin Glargine Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Insulin Glargine players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Insulin Glargine Study Sheds Light on
— The Insulin Glargine Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Insulin Glargine industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Insulin Glargine industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Type 1 Diabetes (T1D)
  • Type 2 Diabetes (T2D)
By Forms
  • Liquid
  • Tablet
  • Syrup
  • Cream
  • Gel

By Side Effect
  • Rash
  • Hives
  • Itching
  • Wheezing

By Distribution Channel
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Sales
  • Other Distribution Channel

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence Of Diabetes Disease
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulatory Requirement For The Approval Of Insulin Glargine
    • 3.4. Market Trends
      • 3.4.1. Increasing Use Of Insulin Glargine For Diabetes Disease
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Insulin Glargine, by Application, Forms, Side Effect , Distribution Channel and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Insulin Glargine (Value)
      • 5.2.1. Global Insulin Glargine by: Application (Value)
        • 5.2.1.1. Type 1 Diabetes (T1D)
        • 5.2.1.2. Type 2 Diabetes (T2D)
      • 5.2.2. Global Insulin Glargine by: Forms (Value)
        • 5.2.2.1. Liquid
        • 5.2.2.2. Tablet
        • 5.2.2.3. Syrup
        • 5.2.2.4. Cream
        • 5.2.2.5. Gel
      • 5.2.3. Global Insulin Glargine by: Distribution Channel (Value)
        • 5.2.3.1. Hospitals Pharmacy
        • 5.2.3.2. Retail Pharmacy
        • 5.2.3.3. Online Sales
        • 5.2.3.4. Other Distribution Channel
      • 5.2.4. Global Insulin Glargine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Insulin Glargine (Price)
  • 6. Insulin Glargine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Cipla Inc. (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi-Aventis (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novo Nordisk (Denmark)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. WOCKHARDT (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Dongbro Pharmaceutical, (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sekisui Diagnostics, LLC, (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biocon Biologics, (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Trumac Healthcare Ltd (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. ADOCIA (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Biogenomics Limited. (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Insulin Glargine Sale, by Application, Forms, Side Effect , Distribution Channel and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Insulin Glargine (Value)
      • 7.2.1. Global Insulin Glargine by: Application (Value)
        • 7.2.1.1. Type 1 Diabetes (T1D)
        • 7.2.1.2. Type 2 Diabetes (T2D)
      • 7.2.2. Global Insulin Glargine by: Forms (Value)
        • 7.2.2.1. Liquid
        • 7.2.2.2. Tablet
        • 7.2.2.3. Syrup
        • 7.2.2.4. Cream
        • 7.2.2.5. Gel
      • 7.2.3. Global Insulin Glargine by: Distribution Channel (Value)
        • 7.2.3.1. Hospitals Pharmacy
        • 7.2.3.2. Retail Pharmacy
        • 7.2.3.3. Online Sales
        • 7.2.3.4. Other Distribution Channel
      • 7.2.4. Global Insulin Glargine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Insulin Glargine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Insulin Glargine: by Application(USD Million)
  • Table 2. Insulin Glargine Type 1 Diabetes (T1D) , by Region USD Million (2018-2023)
  • Table 3. Insulin Glargine Type 2 Diabetes (T2D) , by Region USD Million (2018-2023)
  • Table 4. Insulin Glargine: by Forms(USD Million)
  • Table 5. Insulin Glargine Liquid , by Region USD Million (2018-2023)
  • Table 6. Insulin Glargine Tablet , by Region USD Million (2018-2023)
  • Table 7. Insulin Glargine Syrup , by Region USD Million (2018-2023)
  • Table 8. Insulin Glargine Cream , by Region USD Million (2018-2023)
  • Table 9. Insulin Glargine Gel , by Region USD Million (2018-2023)
  • Table 10. Insulin Glargine: by Distribution Channel(USD Million)
  • Table 11. Insulin Glargine Hospitals Pharmacy , by Region USD Million (2018-2023)
  • Table 12. Insulin Glargine Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 13. Insulin Glargine Online Sales , by Region USD Million (2018-2023)
  • Table 14. Insulin Glargine Other Distribution Channel , by Region USD Million (2018-2023)
  • Table 15. South America Insulin Glargine, by Country USD Million (2018-2023)
  • Table 16. South America Insulin Glargine, by Application USD Million (2018-2023)
  • Table 17. South America Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 18. South America Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 19. South America Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 20. Brazil Insulin Glargine, by Application USD Million (2018-2023)
  • Table 21. Brazil Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 22. Brazil Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 23. Brazil Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 24. Argentina Insulin Glargine, by Application USD Million (2018-2023)
  • Table 25. Argentina Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 26. Argentina Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 27. Argentina Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 28. Rest of South America Insulin Glargine, by Application USD Million (2018-2023)
  • Table 29. Rest of South America Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 30. Rest of South America Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 31. Rest of South America Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 32. Asia Pacific Insulin Glargine, by Country USD Million (2018-2023)
  • Table 33. Asia Pacific Insulin Glargine, by Application USD Million (2018-2023)
  • Table 34. Asia Pacific Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 35. Asia Pacific Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 36. Asia Pacific Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 37. China Insulin Glargine, by Application USD Million (2018-2023)
  • Table 38. China Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 39. China Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 40. China Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 41. Japan Insulin Glargine, by Application USD Million (2018-2023)
  • Table 42. Japan Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 43. Japan Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 44. Japan Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 45. India Insulin Glargine, by Application USD Million (2018-2023)
  • Table 46. India Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 47. India Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 48. India Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 49. South Korea Insulin Glargine, by Application USD Million (2018-2023)
  • Table 50. South Korea Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 51. South Korea Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 52. South Korea Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 53. Australia Insulin Glargine, by Application USD Million (2018-2023)
  • Table 54. Australia Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 55. Australia Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 56. Australia Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 57. Rest of Asia-Pacific Insulin Glargine, by Application USD Million (2018-2023)
  • Table 58. Rest of Asia-Pacific Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 59. Rest of Asia-Pacific Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 60. Rest of Asia-Pacific Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 61. Europe Insulin Glargine, by Country USD Million (2018-2023)
  • Table 62. Europe Insulin Glargine, by Application USD Million (2018-2023)
  • Table 63. Europe Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 64. Europe Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 65. Europe Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 66. Germany Insulin Glargine, by Application USD Million (2018-2023)
  • Table 67. Germany Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 68. Germany Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 69. Germany Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 70. France Insulin Glargine, by Application USD Million (2018-2023)
  • Table 71. France Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 72. France Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 73. France Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 74. Italy Insulin Glargine, by Application USD Million (2018-2023)
  • Table 75. Italy Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 76. Italy Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 77. Italy Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 78. United Kingdom Insulin Glargine, by Application USD Million (2018-2023)
  • Table 79. United Kingdom Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 80. United Kingdom Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 81. United Kingdom Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 82. Netherlands Insulin Glargine, by Application USD Million (2018-2023)
  • Table 83. Netherlands Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 84. Netherlands Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 85. Netherlands Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 86. Rest of Europe Insulin Glargine, by Application USD Million (2018-2023)
  • Table 87. Rest of Europe Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 88. Rest of Europe Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 89. Rest of Europe Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 90. MEA Insulin Glargine, by Country USD Million (2018-2023)
  • Table 91. MEA Insulin Glargine, by Application USD Million (2018-2023)
  • Table 92. MEA Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 93. MEA Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 94. MEA Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 95. Middle East Insulin Glargine, by Application USD Million (2018-2023)
  • Table 96. Middle East Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 97. Middle East Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 98. Middle East Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 99. Africa Insulin Glargine, by Application USD Million (2018-2023)
  • Table 100. Africa Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 101. Africa Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 102. Africa Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 103. North America Insulin Glargine, by Country USD Million (2018-2023)
  • Table 104. North America Insulin Glargine, by Application USD Million (2018-2023)
  • Table 105. North America Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 106. North America Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 107. North America Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 108. United States Insulin Glargine, by Application USD Million (2018-2023)
  • Table 109. United States Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 110. United States Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 111. United States Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 112. Canada Insulin Glargine, by Application USD Million (2018-2023)
  • Table 113. Canada Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 114. Canada Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 115. Canada Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 116. Mexico Insulin Glargine, by Application USD Million (2018-2023)
  • Table 117. Mexico Insulin Glargine, by Forms USD Million (2018-2023)
  • Table 118. Mexico Insulin Glargine, by Side Effect USD Million (2018-2023)
  • Table 119. Mexico Insulin Glargine, by Distribution Channel USD Million (2018-2023)
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Insulin Glargine: by Application(USD Million)
  • Table 131. Insulin Glargine Type 1 Diabetes (T1D) , by Region USD Million (2025-2030)
  • Table 132. Insulin Glargine Type 2 Diabetes (T2D) , by Region USD Million (2025-2030)
  • Table 133. Insulin Glargine: by Forms(USD Million)
  • Table 134. Insulin Glargine Liquid , by Region USD Million (2025-2030)
  • Table 135. Insulin Glargine Tablet , by Region USD Million (2025-2030)
  • Table 136. Insulin Glargine Syrup , by Region USD Million (2025-2030)
  • Table 137. Insulin Glargine Cream , by Region USD Million (2025-2030)
  • Table 138. Insulin Glargine Gel , by Region USD Million (2025-2030)
  • Table 139. Insulin Glargine: by Distribution Channel(USD Million)
  • Table 140. Insulin Glargine Hospitals Pharmacy , by Region USD Million (2025-2030)
  • Table 141. Insulin Glargine Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 142. Insulin Glargine Online Sales , by Region USD Million (2025-2030)
  • Table 143. Insulin Glargine Other Distribution Channel , by Region USD Million (2025-2030)
  • Table 144. South America Insulin Glargine, by Country USD Million (2025-2030)
  • Table 145. South America Insulin Glargine, by Application USD Million (2025-2030)
  • Table 146. South America Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 147. South America Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 148. South America Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 149. Brazil Insulin Glargine, by Application USD Million (2025-2030)
  • Table 150. Brazil Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 151. Brazil Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 152. Brazil Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 153. Argentina Insulin Glargine, by Application USD Million (2025-2030)
  • Table 154. Argentina Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 155. Argentina Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 156. Argentina Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 157. Rest of South America Insulin Glargine, by Application USD Million (2025-2030)
  • Table 158. Rest of South America Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 159. Rest of South America Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 160. Rest of South America Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 161. Asia Pacific Insulin Glargine, by Country USD Million (2025-2030)
  • Table 162. Asia Pacific Insulin Glargine, by Application USD Million (2025-2030)
  • Table 163. Asia Pacific Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 164. Asia Pacific Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 165. Asia Pacific Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 166. China Insulin Glargine, by Application USD Million (2025-2030)
  • Table 167. China Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 168. China Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 169. China Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 170. Japan Insulin Glargine, by Application USD Million (2025-2030)
  • Table 171. Japan Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 172. Japan Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 173. Japan Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 174. India Insulin Glargine, by Application USD Million (2025-2030)
  • Table 175. India Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 176. India Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 177. India Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 178. South Korea Insulin Glargine, by Application USD Million (2025-2030)
  • Table 179. South Korea Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 180. South Korea Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 181. South Korea Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 182. Australia Insulin Glargine, by Application USD Million (2025-2030)
  • Table 183. Australia Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 184. Australia Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 185. Australia Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 186. Rest of Asia-Pacific Insulin Glargine, by Application USD Million (2025-2030)
  • Table 187. Rest of Asia-Pacific Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 188. Rest of Asia-Pacific Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 189. Rest of Asia-Pacific Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 190. Europe Insulin Glargine, by Country USD Million (2025-2030)
  • Table 191. Europe Insulin Glargine, by Application USD Million (2025-2030)
  • Table 192. Europe Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 193. Europe Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 194. Europe Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 195. Germany Insulin Glargine, by Application USD Million (2025-2030)
  • Table 196. Germany Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 197. Germany Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 198. Germany Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 199. France Insulin Glargine, by Application USD Million (2025-2030)
  • Table 200. France Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 201. France Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 202. France Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 203. Italy Insulin Glargine, by Application USD Million (2025-2030)
  • Table 204. Italy Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 205. Italy Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 206. Italy Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 207. United Kingdom Insulin Glargine, by Application USD Million (2025-2030)
  • Table 208. United Kingdom Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 209. United Kingdom Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 210. United Kingdom Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 211. Netherlands Insulin Glargine, by Application USD Million (2025-2030)
  • Table 212. Netherlands Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 213. Netherlands Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 214. Netherlands Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 215. Rest of Europe Insulin Glargine, by Application USD Million (2025-2030)
  • Table 216. Rest of Europe Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 217. Rest of Europe Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 218. Rest of Europe Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 219. MEA Insulin Glargine, by Country USD Million (2025-2030)
  • Table 220. MEA Insulin Glargine, by Application USD Million (2025-2030)
  • Table 221. MEA Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 222. MEA Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 223. MEA Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 224. Middle East Insulin Glargine, by Application USD Million (2025-2030)
  • Table 225. Middle East Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 226. Middle East Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 227. Middle East Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 228. Africa Insulin Glargine, by Application USD Million (2025-2030)
  • Table 229. Africa Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 230. Africa Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 231. Africa Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 232. North America Insulin Glargine, by Country USD Million (2025-2030)
  • Table 233. North America Insulin Glargine, by Application USD Million (2025-2030)
  • Table 234. North America Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 235. North America Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 236. North America Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 237. United States Insulin Glargine, by Application USD Million (2025-2030)
  • Table 238. United States Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 239. United States Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 240. United States Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 241. Canada Insulin Glargine, by Application USD Million (2025-2030)
  • Table 242. Canada Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 243. Canada Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 244. Canada Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 245. Mexico Insulin Glargine, by Application USD Million (2025-2030)
  • Table 246. Mexico Insulin Glargine, by Forms USD Million (2025-2030)
  • Table 247. Mexico Insulin Glargine, by Side Effect USD Million (2025-2030)
  • Table 248. Mexico Insulin Glargine, by Distribution Channel USD Million (2025-2030)
  • Table 249. Research Programs/Design for This Report
  • Table 250. Key Data Information from Secondary Sources
  • Table 251. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Insulin Glargine: by Application USD Million (2018-2023)
  • Figure 5. Global Insulin Glargine: by Forms USD Million (2018-2023)
  • Figure 6. Global Insulin Glargine: by Distribution Channel USD Million (2018-2023)
  • Figure 7. South America Insulin Glargine Share (%), by Country
  • Figure 8. Asia Pacific Insulin Glargine Share (%), by Country
  • Figure 9. Europe Insulin Glargine Share (%), by Country
  • Figure 10. MEA Insulin Glargine Share (%), by Country
  • Figure 11. North America Insulin Glargine Share (%), by Country
  • Figure 12. Global Insulin Glargine share by Players 2023 (%)
  • Figure 13. Global Insulin Glargine share by Players (Top 3) 2023(%)
  • Figure 14. Global Insulin Glargine share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Cipla Inc. (India) Revenue, Net Income and Gross profit
  • Figure 17. Cipla Inc. (India) Revenue: by Geography 2023
  • Figure 18. Sanofi-Aventis (France) Revenue, Net Income and Gross profit
  • Figure 19. Sanofi-Aventis (France) Revenue: by Geography 2023
  • Figure 20. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 21. Novo Nordisk (Denmark) Revenue: by Geography 2023
  • Figure 22. WOCKHARDT (India) Revenue, Net Income and Gross profit
  • Figure 23. WOCKHARDT (India) Revenue: by Geography 2023
  • Figure 24. Dongbro Pharmaceutical, (China) Revenue, Net Income and Gross profit
  • Figure 25. Dongbro Pharmaceutical, (China) Revenue: by Geography 2023
  • Figure 26. Sekisui Diagnostics, LLC, (United States) Revenue, Net Income and Gross profit
  • Figure 27. Sekisui Diagnostics, LLC, (United States) Revenue: by Geography 2023
  • Figure 28. Biocon Biologics, (India) Revenue, Net Income and Gross profit
  • Figure 29. Biocon Biologics, (India) Revenue: by Geography 2023
  • Figure 30. Trumac Healthcare Ltd (India) Revenue, Net Income and Gross profit
  • Figure 31. Trumac Healthcare Ltd (India) Revenue: by Geography 2023
  • Figure 32. ADOCIA (France) Revenue, Net Income and Gross profit
  • Figure 33. ADOCIA (France) Revenue: by Geography 2023
  • Figure 34. Biogenomics Limited. (India) Revenue, Net Income and Gross profit
  • Figure 35. Biogenomics Limited. (India) Revenue: by Geography 2023
  • Figure 36. Global Insulin Glargine: by Application USD Million (2025-2030)
  • Figure 37. Global Insulin Glargine: by Forms USD Million (2025-2030)
  • Figure 38. Global Insulin Glargine: by Distribution Channel USD Million (2025-2030)
  • Figure 39. South America Insulin Glargine Share (%), by Country
  • Figure 40. Asia Pacific Insulin Glargine Share (%), by Country
  • Figure 41. Europe Insulin Glargine Share (%), by Country
  • Figure 42. MEA Insulin Glargine Share (%), by Country
  • Figure 43. North America Insulin Glargine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Cipla Inc. (India)
  • Sanofi-Aventis (France)
  • Novo Nordisk (Denmark)
  • WOCKHARDT (India)
  • Dongbro Pharmaceutical, (China)
  • Sekisui Diagnostics, LLC, (United States)
  • Biocon Biologics, (India)
  • Trumac Healthcare Ltd (India)
  • ADOCIA (France)
  • Biogenomics Limited. (India)
Select User Access Type

Key Highlights of Report


Mar 2024 209 Pages 74 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Insulin Glargine Quantitative research analysis
Global Insulin Glargine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2023; Base year: 2023; Forecast period: 2024 to 2030
Companies that are profiled in Global Insulin Glargine Market are Cipla Inc. (India), Sanofi-Aventis (France), Novo Nordisk (Denmark), WOCKHARDT (India), Dongbro Pharmaceutical, (China), Sekisui Diagnostics, LLC, (United States), Biocon Biologics, (India), Trumac Healthcare Ltd (India), ADOCIA (France) and Biogenomics Limited. (India) etc.
Type 1 Diabetes (T1D) segment in Global market to hold robust market share owing to "Rising Prevalence Of Diabetes Disease".
AMA Research predicts that Indian Players will contribute to the maximum growth of Global Insulin Glargine market throughout the forecasted period.

Know More About Global Insulin Glargine Report?

Have a Query? Click Here

Other Related Reports

Topical Pain Relief Comprehensive Study by Type (Prescription Pain Relief Products, Over-the-counter (OTC) Pain Relief Products), Application (Pets, Mammals, Farm Animals), Distribution Channel (Phar...
$ 3650
Atenolol Tablets Comprehensive Study by Application (Hypertension, Angina, Arrhythmias), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Prescription Mode (Prescript...
$ 3450
TB Vaccines Comprehensive Study by Type (Attenuated, Booster), Application (Hospitals, Clinical Labs, Pharmaceuticals), Distribution Channel (Online, Offline), Age Group (Pediatric, 16 Years – 35 Yea...
$ 3800
Atovaquone Comprehensive Study by Type (750mg, 5mL Oral suspension, 250mg/100mg, 62.5mg/25mg), Application (Ant malarial treatment, Pneumonia (Pneumocystis carinii), Others), Distribution Channel (On...
$ 3750
Terbinafine Hydrochloride Drug Comprehensive Study by Application (Athlete's Foot, Jock Itch, Ringworm, Others), Route of Administration (Topical, Oral), Duration of therapy (Fingernail onychomycosis...
$ 3450
Specialty Supplements Comprehensive Study by Application (Skin Care, Hair Care, Nutritional Deficiency, Cardiac Care, Mind Care, Others), Sales (Online, Offline), Form (Liquid, Powder, Capsule), Ingr...
$ 3450